GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

YM087

Company
Cumberland Pharmaceuticals
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT00057356

    Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure

    Not yet reported Cumberland Pharmaceuticals 170 participants Est. completion 2004-03 26 sites
    Heart failure
    View official trial listing →
  • Completed NCT NCT00379847

    An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic Hyponatremia

    Not yet reported Cumberland Pharmaceuticals 251 participants Est. completion 2005-06 28 sites
    Other conditions: Hyponatremia
    View official trial listing →
  • Completed NCT NCT00380575

    Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia

    Not yet reported Cumberland Pharmaceuticals 84 participants Est. completion 2003-02 47 sites
    Other conditions: Hyponatremia
    View official trial listing →
  • Completed NCT NCT00435591

    A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

    Not yet reported Cumberland Pharmaceuticals 121 participants Est. completion 2008-09 18 sites
    Other conditions: Hyponatremia, Euvolemia, Hypervolemia
    View official trial listing →
  • Completed NCT NCT00478192

    Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia

    Not yet reported Cumberland Pharmaceuticals 50 participants Est. completion 2008-08 26 sites
    Other conditions: Hyponatremia
    View official trial listing →
  • Completed NCT NCT00492037

    Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia

    Not yet reported Cumberland Pharmaceuticals 83 participants Est. completion 2002-02 29 sites
    Other conditions: Hyponatremia
    View official trial listing →
  • Completed NCT NCT00592475

    A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients

    Not yet reported Cumberland Pharmaceuticals 20 participants Est. completion 2008-11 1 site
    Other conditions: Liver Cirrhosis
    View official trial listing →
  • Withdrawn NCT NCT00684164

    Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients

    Not yet reported Columbia University Est. completion 2010-06 1 site
    Other conditions: Hyponatremia
    View official trial listing →
  • Terminated NCT NCT00727090

    Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients

    Not yet reported Northwestern University 6 participants Est. completion 2010-02
    Other conditions: Hyponatremia
    View official trial listing →
  • Withdrawn NCT NCT00806910

    Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion

    Not yet reported Albert Einstein Healthcare Network Est. completion 2010-02
    Heart failure
    View official trial listing →
  • Withdrawn NCT NCT00811486

    Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure

    Not yet reported University of Colorado, Denver Est. completion 2010-12 1 site
    Heart failure Other conditions: Pulmonary Hypertension
    View official trial listing →
  • Terminated NCT NCT00843986

    Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)

    Not yet reported Cumberland Pharmaceuticals 9 participants Est. completion 2009-08 4 sites
    Heart failure Other conditions: Hyponatremia
    View official trial listing →
  • Completed NCT NCT00851227

    Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function

    Not yet reported Cumberland Pharmaceuticals 26 participants Est. completion 2010-01 1 site
    Other conditions: Liver Disease, Hyponatremia
    View official trial listing →
  • Completed NCT NCT00887627

    Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function

    Not yet reported Cumberland Pharmaceuticals 25 participants Est. completion 2010-07 1 site
    Other conditions: Kidney Diseases, Hyponatremia
    View official trial listing →
  • Status unknown NCT NCT00924014

    Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure

    Not yet reported Hennepin County Medical Center, Minneapolis 8 participants Est. completion 2010-03 1 site
    Heart failure
    View official trial listing →
  • Completed NCT NCT00930202

    Study of the Safety and Efficacy of Conivaptan (Vaprisol®) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury

    Not yet reported University of Washington 10 participants Est. completion 2010-06 1 site
    Other conditions: Severe Traumatic Brain Injury
    View official trial listing →
  • Completed NCT NCT01370148

    A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan

    Not yet reported Cumberland Pharmaceuticals 17 participants Est. completion 2014-02 3 sites
    Other conditions: Liver Disease
    View official trial listing →
  • Terminated NCT NCT01451411

    A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia

    Not yet reported Cumberland Pharmaceuticals 4 participants Est. completion 2014-01 3 sites
    Other conditions: Hyponatremia
    View official trial listing →
  • Completed NCT NCT01752543

    Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients

    Not yet reported Finn Gustafsson 20 participants Est. completion 2015-06 1 site
    Heart failure
    View official trial listing →
  • Withdrawn NCT NCT01954290

    Study of Stroke Related Edema Treatments

    Not yet reported University of Florida Est. completion 2015-09
    Other conditions: Acute Cerebrovascular Accident, Cerebral Edema
    View official trial listing →
  • Completed NCT NCT03000283

    Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

    Not yet reported Jesse Corry 7 participants Est. completion 2019-04-15 1 site
    Cardiovascular disease Other conditions: Cerebral Hemorrhage, Cerebral Edema, Intracerebral Hemorrhage
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.